Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Andy Pearce, Director of Discovery Partnerships with Academia at GSK joins the scheme as a Drug Discovery and Development Expert

Andy Pearce

The Business Development Team for the Medical Sciences Division has announced the appointment of a new  expert to its Industry Experts in Residence Scheme. Dr Andy Pearce, Director of Discovery Partnerships with Academia at GSK, joined the scheme in October. 

In his role Dr Pearce leads drug discovery projects from target validation through hit-finding and to the delivery of high quality clinical candidates, across broad disease areas, in collaboration with world-leading academic partners. He is a biochemist and cell biologist by training, and received his undergraduate degree and DPhil from the University of Oxford before undertaking postdoctoral studies at the University of Birmingham. Dr Pearce is a Fellow of the Royal Society of Biology, and he occasionally lectures at Oxford and Cambridge Universities and participates in career panels and workshops for scientists.

Dr Pearce said: ‘I am really excited to be taking up the position of Expert in Residence in Drug Discovery and Development. I am looking forward to meeting Oxford colleagues, discussing some of their great science, and contributing whatever I can to help advance Translational Research in Oxford towards medicines to benefit patients’.

The Industry Experts in Residence programme is managed by the MSD Business Development Team and Oxford University Innovation. It aims to give Oxford's research community access to world-leading expertise and advice across multiple sectors. Researchers can arrange meetings with industry experts to discuss their ideas and projects, and attend seminars given by these experts on a wide range of topics.

The scheme currently hosts experts in product design in biomedical engineering, drug discovery, and digital health, and the appointment of Dr Pearce has made his expertise in Drug Discovery and Development available to researchers. Dr Pearce will sit in the Target Discovery Institute (TDI), Nuffield Department of Medicine, NDM Research Building on various dates during 2018/19. If you would like to arrange a meeting please contact charlotte.bell@medsci.ox.ac.uk

Maxine Allen, Head of Business Development and Partnering for the Medical Sciences Division, commented: 'The Industry Experts in Residence scheme is a fantastic opportunity for our researchers to develop translational strategies for their projects, and an innovative way to foster interaction between industry and academia.

'Find out more about the scheme and book an appointment with an expert 

Similar stories

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Evox Therapeutics announces launch of strategic collaboration with the University of Oxford

General Innovation

Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases

BioEscalator’s resident biotech Base Genomics acquired by Exact Sciences

General Innovation

Oxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.